Alpha-MSH and Its Fragment KPV Kill Bacteria and Fungi as Part of the Body's Innate Defense
Alpha-MSH and its C-terminal tripeptide KPV showed antimicrobial activity against Staphylococcus aureus, Candida albicans, and E. coli, revealing a new defense role for this anti-inflammatory peptide.
Quick Facts
What This Study Found
Alpha-MSH and its C-terminal tripeptide fragment KPV demonstrated direct antimicrobial activity against S. aureus, C. albicans, and E. coli, establishing a dual anti-inflammatory/antimicrobial function for this neuropeptide.
Key Numbers
How They Did This
In-vitro antimicrobial testing of alpha-MSH (1-13) and KPV (11-13) against S. aureus, C. albicans, and E. coli using standard microbiological assays.
Why This Research Matters
A peptide that is simultaneously anti-inflammatory AND antimicrobial is uniquely suited for protecting barrier organs like skin and gut, where infection and inflammation often coexist.
The Bigger Picture
The body's innate defense at barrier surfaces needs to fight microbes while controlling inflammation. Alpha-MSH/KPV does both simultaneously, representing an elegant evolutionary solution to the challenge of barrier immunity.
What This Study Doesn't Tell Us
In-vitro antimicrobial testing. Concentrations achieving antimicrobial effects may differ from physiological levels. Mechanism of antimicrobial action not fully characterized.
Questions This Raises
- ?Is alpha-MSH/KPV antimicrobial activity sufficient at physiological concentrations?
- ?Could KPV be developed as a topical antimicrobial/anti-inflammatory agent?
- ?Does alpha-MSH deficiency increase susceptibility to skin or gut infections?
Trust & Context
- Key Stat:
- Dual function Alpha-MSH/KPV is both antimicrobial (kills Staph, Candida, E. coli) AND anti-inflammatory — uniquely suited for barrier organ defense
- Evidence Grade:
- Preliminary in-vitro evidence demonstrating direct antimicrobial activity for a peptide already known for anti-inflammatory effects.
- Study Age:
- Published in 2000. KPV has since gained significant interest as a therapeutic peptide for gut inflammation (IBD) and skin conditions.
- Original Title:
- The neuropeptide alpha-MSH in host defense.
- Published In:
- Annals of the New York Academy of Sciences, 917, 227-31 (2000)
- Authors:
- Catania, A(3), Cutuli, M(2), Garofalo, L, Carlin, A, Airaghi, L, Barcellini, W, Lipton, J M
- Database ID:
- RPEP-00586
Evidence Hierarchy
Frequently Asked Questions
What is KPV?
KPV is just three amino acids (Lys-Pro-Val) from the end of alpha-MSH. Despite being tiny, it retains both the anti-inflammatory and antimicrobial properties of the full peptide, making it an attractive therapeutic candidate.
How can such a small peptide kill bacteria?
Many antimicrobial peptides work by disrupting bacterial membranes. KPV's positively charged structure allows it to interact with and damage the negatively charged bacterial cell surface, a fundamental antimicrobial mechanism.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00586APA
Catania, A; Cutuli, M; Garofalo, L; Carlin, A; Airaghi, L; Barcellini, W; Lipton, J M. (2000). The neuropeptide alpha-MSH in host defense.. Annals of the New York Academy of Sciences, 917, 227-31.
MLA
Catania, A, et al. "The neuropeptide alpha-MSH in host defense.." Annals of the New York Academy of Sciences, 2000.
RethinkPeptides
RethinkPeptides Research Database. "The neuropeptide alpha-MSH in host defense." RPEP-00586. Retrieved from https://rethinkpeptides.com/research/catania-2000-the-neuropeptide-alphamsh-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.